key: cord-0726845-4elisewv
authors: Weber, F.
title: Antiviral Innate Immunity: Introduction☆
date: 2014-12-31
journal: Reference Module in Biomedical Sciences
DOI: 10.1016/b978-0-12-801238-3.02608-8
sha: 62cb3b94575ff24fbefa4168b009ac22b3350b37
doc_id: 726845
cord_uid: 4elisewv

Abstract The concept of ‘innate immunity’ embraces all sorts of measures that exclude, inhibit, or slow down infections with little specificity and without adaptation or generation of a long-lasting memory. The mammalian innate immune defenses described in this article comprise defensins, the complement system, nonspecific phagocytic and cytolytic leukocytes (macrophages, monocytes, granulocytes, natural killer cells, and dendritic cells), and cytokines such as the antivirally active interferons. Since the type I interferon (IFN-α/β) system is our primary defense against viral infections, special attention will be paid to the virus-triggered induction of IFN transcription, the signaling activated by IFNs, and the antiviral factors expressed as a consequence

Viruses attempting to conquer a mammalian body are faced with an array of problems. 'Innate immunity' in a wider sense comprises all sorts of factors which exclude, inhibit, or slow down infections in a rapid manner but with little specificity and without adaptation or generation of a protective memory. Many of these efficient and not at all primitive defenses are evolutionarily old and can be found in all metazoans. For the sake of brevity, however, the discussion in this article is restricted to mammals as these are the best investigated organisms in that respect. RNA interference, the innate immune system of plants and non-vertebrates, is not covered here. Mammalian innate immune defenses against virus infections can be divided into several distinct parts such as mechanical and chemical barriers (not further mentioned here), defensins, complement system, phagocytic/cytolytic cells of the immune system which act in a nonspecific manner, and cytokines (most prominently the type I IFN).

induced by viral infection. Their common antimicrobial function is the formation of destructive pores in membranes of pathogens including enveloped viruses. Defensins can however also block infection by enveloped and non-enveloped viruses alike by aggregating the particles, blocking receptor binding, inhibiting virus entry or particle uncoating, interfere with essential cell signaling or viral gene expression, or act by other, ill-understood mechanisms. Moreover, defensins were shown to attract immune cells and modulate adaptive immune responses.

The complement system (which 'complements' the adaptive immune system in the defense against pathogens) primes the adaptive immune response and is also directly effective against pathogens. Complement activation is achieved by specific receptors recognizing pathogens or immunocomplexes. Three different pathways are being distinguished which are termed the classical pathway (triggered by antigen-antibody complexes), the mannan-binding lectin pathway (triggered by lectin binding of pathogen surfaces), and the alternative pathway (triggered by complement factor C3b-coated pathogen surfaces). They all activate a cascade of reactions involving more than 20 soluble and cell-bound proteins, thus resulting in a rapid and massive response. The complement system is able to (1) tag infected cells and pathogens for destruction by phagocytic cells (opsonization), (2) prime humoral immune responses, and (3) perforate membranes of infected cells by the membrane-attack complex. In response, viruses have evolved effective countermeasures such as incorporation of cellular complement-regulatory proteins into particles or expressing specific inhibitors in infected cells.

Macrophages/monocytes, granulocytes, natural killer cells, and dendritic cells belong to the cellular branch of the innate immune system. Monocytes circulate in the bloodstream for several hours before they differentiate into macrophages. These potent phagocytic cells either continue patrolling or they permanently settle in particular tissues (i.e., the Kupffer cells of the liver), being able to rapidly remove viral particles and apoptotic bodies. Activated macrophages also synthesize inflammatory cytokines such as IFN-g and tumor necrosis factor (TNF)-a, thus triggering an adaptive immune response. Granulocytes are also able to remove viral particles and apoptotic bodies by phagocytosis. They are rapidly attracted to inflammatory sites and enter the tissue by transendothelial migration. Both macrophages and granulocytes cleave the ingested viral proteins into fragments and present them to T lymphocytes.

Natural killer (NK) cells are able to recognize infected cells in an antigen-independent manner and destroy them by their cytotoxic activity. Also, they rapidly produce large amounts of IFN-g to activate the adaptive immune system. NK cells are regulated by a fine balance between stimulatory and inhibitory receptors. One of their prominent features is their ability to destroy cells which lack MHC I molecules on their surface. As many viruses downregulate MHC expression in order to avoid an adaptive immune response, NK surveillance represents an important early warning and attack system against virus infections.

A key connection between the innate and the adaptive immune system is provided by dendritic cells (DCs). These specialized immune cells sample antigen at the site of infection, activate themselves and the surrounding tissue cells by cytokine synthesis, and then migrate to secondary lymphatic organs in order to mobilize T cells against the presented antigen. The differentiation into efficient antigen-presenting cells (APCs) is achieved by cytokine production which, in turn, is triggered by stimulation of receptors recognizing pathogen-specific molecular patterns (PAMPs). Two main types of DCs are being distinguished: myeloid DCs (mDCs) and plasmacytoid DCs (pDCs). mDCs are an early split-off of the myeloid bone marrow precursors, that is, the stem cells which are also giving birth to macrophages/monocytes and granulocytes, among others. Depending on the location, several subsets of mDCs such as Langerhans cells or interstitial cells are being distinguished. pDCs, which are not segregated into subpopulations, are thought to be derived from lymphatic precursor cells. Both mDCs and pDCs can sense viral infection by several intra-and extracellular PAMP receptors (see below). Depending on the DC type, high levels of interleukins or IFNs are being produced which coin the subsequent immune reaction. pDCs are potent producers of the main antiviral cytokines, the type I IFNs.

Isaacs and Lindenmann discovered in 1957 that cells which had been in contact with virus particles secrete a soluble factor which confers resistance to influenza viruses, a phenomenon called 'interference'. In the subsequent years, it became more and more clear that the so-called type I IFN (encompassing IFN-b and a set of IFN-a subtypes) system is our primary defense mechanism against viral infections. In fact, humans with genetic defects in the IFN signaling pathway have a bad prognosis as they die at an early age of viral diseases which would otherwise pose little problems. Similarly, knockout mice with a defective IFN system quickly succumb to viral pathogens of all sorts although they have an intact adaptive immune system.

In response to virus infection, pDCs are particularly well equipped to synthesize and secrete IFN-a/b, but in principle all nucleated cells are able to do so. In an autocrine and paracrine manner, IFNs trigger a signaling chain leading to the expression of potent antiviral proteins which limit further viral spread. In addition, IFNs initiate, modulate, and enhance the adaptive immune response. The signaling events which culminate in the direct IFN-dependent restriction of virus growth can be divided into three steps, namely (1) transcriptional induction of IFN synthesis, (2) IFN signaling, and (3) antiviral mechanisms.

Nucleic acids are the main PAMPs of viruses, being recognized by a number of pattern recognition receptors (PRRs) to initiate induction of IFN genes (see Figure 1 ). Classes of virus-triggered PRRs can be divided into the endosomal toll-like receptors (TLRs) and various intracellular (mostly cytoplasmic) receptors. Although the viral genome is protected by a nucleocapsid and often a lipid envelope, it is thought that a fraction of the virus particles (or endocytosed remnants of infected cells) gets lysed by the endosomal low pH and/or degradative enzymes to release the viral nucleic acids. Major PAMPs are double-stranded RNA (dsRNA), singlestranded RNA (ssRNA), 5'-triphosphorylated (ppp) RNAs, and double-stranded DNA (dsDNA). dsRNA and 5'ppp-RNA are not present in uninfected cells, thus predestining them as a immunorelevant markers of non-self. In the case of ssRNA and dsDNA, it is thought that unusual locations (e.g. endosome or cytoplasm for DNA), a lack of cell-typical modifications (e.g. methylation), or specific secondary structures are responsible for triggering antiviral responses. Moreover it should be noted that a full-blown infection converts the heterogeneous population of cellular nucleic acids into a pool of largely homogeneous, highly abundant viral molecules. Thus immunogenicity could also be caused by over-representation of uniform RNA or DNA species.

dsRNA is an almost ubiquitous transcriptional by-product of RNA and DNA viruses. In the endosome it is recognized by TLR3, and in the cytoplasm by the RNA helicases RIG-I and MDA-5 (collectively termed RIG-I-like receptors, RLRs) and the protein kinase PKR.

Viruses with a negative-strand ssRNA genome (e.g., influenza virus) are unique in that they do not produce substantial amounts of long dsRNA. Their genomic ssRNA is recognized in the endosome by TLR7 and -8. In the cytoplasm, the viral genomes are recognized by RIG-I in a 5 0 -triphosphate-dependent manner. Recent investigations revealed that a short dsRNA region, formed by the annealing of complementary 5' and 3' ends of the RNA genome (the so-called "panhandle"), is essential for RIG-I to be activated.

The third important PAMP, viral dsDNA, is again recognized both by an endosomal receptor, TLR9, and a series of intracellular receptors such as e.g. IFI16, DDX41, RNA polymerase III, and cGAS. dsDNA recognition by RNA polymerase III actually represents a crosstalk between the RNA-PRRs and the DNA-PRRs, since the polymerase transcribes viral DNA into 5'ppp-dsRNA which then activates RIG-I. A similar second messenger principle is realized by cGAS (cGAMP synthase) which produces cyclic di-GMP-AMP (cGAMP) molecules in response to cytoplasmic dsDNA. cGAMP, in turn, activates downstream signaling.

Besides nucleic acids, some viral proteins can provoke a TLR response such as the envelope proteins of respiratory syncytial virus and measles virus by activating TLR4 and TLR2, respectively.

All PRRs are triggering signaling chains (with partial crosstalk and usage of common adaptors and kinases) which culminate in a strong activation the IFN regulatory factor (IRF) -3, and the general immune-regulatory transcription factor NF-kB. Together, IRF-3 and NF-kB upregulate IFN gene expression. This leads to a 'first wave' of IFN production (IFN-b and IFN-a4 in mice) which triggers the expression of the transcription factor IRF-7. IRF-7 is a master regulator of IFN gene expression cooperating with IRF-3 for full activity. IRF-7 can be activated in the same way as IRF-3 and is responsible for a positive-feedback loop that initiates the synthesis of several IFN-a subtypes as the 'second-wave' IFNs.

While all cells with a nucleus are thought to be equipped with the set of intracellular PRRs, expression of TLRs is more restricted to epithelial and immune cells. mDCs, for example, can sense dsRNA by the classic intracellular pathway and, in addition, by TLR3. pDCs sense the presence of viral ssRNA or dsDNA by TLR7, TLR8, and TLR9 to transcriptionally activate multiple IFN-a genes via IRF-7. In contrast to other cell types, pDCs contain considerable amounts of constitutively expressed IRF-7. IRF-7 is further upregulated in response to IFN and generates a positive-feedback loop for high IFN-a and IFN-b production. Furthermore, TLR7 and TLR9 are retained in the endosomes of pDCs to allow prolonged IFN induction signaling.

IFN-b and the multiple IFN-a subspecies activate a common type I IFN receptor (IFNAR) which signals to the nucleus through the so-called JAK-STAT pathway (Figure 2) . The signal transducer and activator of transcription (STAT) proteins are latent cytoplasmic transcription factors which become phosphorylated by the Janus kinases JAK1 and TYK2. Phosphorylated STAT1 and STAT2 recruit a third factor, IRF9, to form a complex known as IFN-stimulated gene factor 3 (ISGF3) which translocates to the nucleus and binds to the IFN-stimulated response element (ISRE) in the promoter region of interferon-stimulated genes (ISGs).

Type I IFNs activate the expression of several hundred IFN-stimulated genes (ISGs) with multiple functions. To date, only a fraction of these antiviral pathways has been studied in great detail, for example the 2'-5' OAS/RNaseL system, ISG20, the Mx proteins, the RNA-specific adenosine deaminase 1 (ADAR 1), the protein kinase R (PKR), and IFN-induced tetratricopeptide repeat (IFIT) protein 1. 2'-5' OAS, ADAR, and PKR are constitutively expressed in normal cells in a latent, inactive form. Basal mRNA levels are upregulated by IFN-a/b and these enzymes need to be activated by viral dsRNA. The 2'-5' OAS catalyzes the synthesis of short 2 0 -5 0 oligoadenylates that activate the latent endoribonuclease RNaseL. RNaseL degrades both viral and cellular RNAs, leading to virus inhibition. ADAR 1 catalyzes the deamination of adenosine on target dsRNAs to yield inosine. As a result the secondary structure is destabilized due to a change from an AU base pair to the less stable IU base pair and mutations accumulate within the viral genome. PKR is a serine-threonine kinase that phosphorylates -among other substrates -the a-subunit of the eukaryotic translation initiation factor eIF2 to block translation of cellular and viral mRNAs. PKR also plays a role in virus-induced NF-kB activation, as described above. ISG20 is an exonuclease that degrades viral ssRNA. IFIT1 is expressed at extremely high levels after IFN stimulation or PRR signaling and sequesters viral RNA with a 5'ppp end or an unmethylated cap. Mx proteins are enwrapping viral nucleocapsids, thus preventing the viral polymerase from elongation of transcription.

The antiviral profiles of the IFN effectors listed above are distinct but often overlapping. Mx proteins, for example, mainly inhibit segmented negative-strand RNA viruses and also Semliki Forest virus, whereas the 2'-5' OAS/RNaseL system appears more important against positive-strand RNA viruses. Moreover, only rarely the presence of one particular IFN effector determines host resistance. Rather, it is the sum of antiviral factors affecting, for example, genome stability, genetic integrity, transcription, and translation that confers the full antiviral power of IFN. 

Besides the effector proteins listed above, several ISGs contribute in a more indirect manner to the enhancement of both innate and adaptive immune responses. Virus-sensing (and in part antiviral) PRRs such as TLR3, PKR, RIG-I, and MDA5 are by themselves upregulated in an IFN-dependent manner. Similarly, IRF-7 and and STAT1, the key factors of type I IFN and ISG transcription, respectively, are ISGs. The strong positive-feedback loop mediated by the upregulation of these PRRs and transcription factors is counterbalanced by several negative regulators (e.g. LGP2, SOCS, PIAS), which are either ISGs or depend on IFN signaling for their suppressive action.

Type I IFNs can directly enhance clonal expansion and memory formation of CD8 + T cells. Also, IFNs promote NK cellmediated cytotoxicity and trigger the synthesis of other cytokines such as IFN-g or IL-15 which modulate the adaptive immune response, enhance NK cell proliferation, and support CD8 + T-cell memory. Moreover, by upregulating TLRs, MHCs, and costimulatory molecules, IFNs enable APCs (most prominently DCs) to become competent in presenting viral antigens and stimulating the adaptive immune response.

Given the massive direct and indirect antiviral effects of type I IFNs, it comes as no surprise that viruses had evolved efficient countermeasures. In fact, most viruses investigated so far were found to actively inhibit either IFN induction, IFN signaling, antiviral ISG action, or combinations thereof. A common strategy to avoid IFN induction seems to be the targeting of treacherous dsRNA or 5'ppp structures by binding, modifying or degradation through viral factors, the so-called IFN antagonists. Moreover, many viral features such as encapsidating genomic RNA by nucleoprotein (negative-strand RNA viruses), hiding replication complexes in intracellular membrane enclosures (positive-strand RNA viruses) or multiple protein sheets (dsRNA viruses), as well as replicating in the nucleus (orthomyxoviruses) can be regarded as passive strategies to minimize generation and exposure of PAMPs to PRRs. Active strategies include sequestration or proteasomal degradation of key factors of antiviral signaling like PRRs, kinases, IRFs, STATs or even RNA polymerase II itself. The bundle of these measures, i.e. the individual anti-IFN profile of a particular virus, can represent a major marker for host range, cell tropism, and virulence. Weak anti-IFN capabilities would render a virus unfit in a given host, whereas strong IFN suppression enables productive replication. However, while this might be a rule of thumb for viruses causing acute infections, a different picture is presented in persistent infections. Here, long-term production of IFN is beneficial for the virus as it results in an immunosuppression aimed at limiting immunopathology. Thus, the balance and timing of activation vs. suppression of the IFN response can determine the outcome of infection, ranging from a straight fending off (host wins by early antiviral IFN action) to acute disease (virus wins by suppressing early IFN action) to chronic viral disease (constant IFN levels maintain infection by suppressing immune responses). In any case, the simple equation: strong IFN antagonism ¼ virulent virus, weak IFN antagonism ¼ harmless virus, should be applied with some caution.

Given their massive impact on the cellular gene expression profile, it is quite expected that type I IFNs have not only antiviral, but also antiproliferative and immunomodulatory effects. Treatment with IFNs is an established therapy against several viral and malignant diseases such as hepatitis B, hepatitis C, Kaposi's sarcoma, papillomas, multiple sclerosis, and several leukemias and myelomas. However, the strong and systemic effects of IFNs do not come without a price. Administration of IFN can locally produce inflammation, and systemically cause fever, fatigue, malaise, myalgia, and anemia. It is no coincidence that these latter are 'flu-like' symptoms, since in many acute infections IFNs play a dominant role. The effects of IFN which are desired and beneficial if restricted to the site of first infection can turn into a life-threatening 'cytokine storm' if it becomes systemic. Severe acute respiratory syndrome (SARS) and human infections with H5N1 influenza viruses are examples of such out-of-control innate immune responses. Moreover, the effect of long-term IFN levels facilitating persistent infections was discussed above. Another 'dark side' aspect is that patients with autoimmune diseases have chronically elevated levels of IFNs, and that IFN therapy can aggravate autoimmune disorders. It is thought that pDCs (and in part B cells) are autostimulated by self-DNA via TLR9 and by small nuclear RNA complexes (snRNPs) via TLR7. Chronic production of IFNs causes maturation of mDCs, which in turn activate autoreactive T and B cells.

The concept of innate immunity certainly comprises more than the IFN system (see above), but type I IFNs represent a central part. These cytokines not only have direct antiviral effects but also orchestrate the first defense reactions and the subsequent adaptive immune response, thus determining the course of infection. The fact that basically every virus appears to have evolved one or several countermeasures for controlling the IFN response is testament to its importance. In addition, IFNs are not only antiviral, but also effective tumor suppressors. Tumor cells often eliminate the IFN system during the transformation process. The payoff is an increased susceptibility to infection, an Achilles heel which is exploited by the therapeutic concept of oncolytic viruses. Tumor selectivity of such viruses can be even more increased by using IFN-sensitive mutants. The inability of those mutants to fight the IFN response is complemented by the mutations of the tumor cells, thus allowing virus growth. At the same time, these viruses are unable to infect the IFN-competent healthy cells.

In the recent years it became apparent that there exists a hitherto unnoticed parallel world, the type III IFN system. The cytokines IFN-l1, -l2, and -l3 are induced by virus PAMPs and signal through the JAK/STAT cascade, but use a separate receptor. Type III IFNs are able to activate antiviral gene expression and have been shown to inhibit replication of respiratory, enteric, and hepatotropic viruses. However, whereas all nucleated cells express IFNAR and can hence respond to type I IFN, expression of the type III IFN receptor is limited to epithelial cells and hepatocytes. Thus, at anatomical sites which are most exposed to viral intruders the IFN response has a backup system enforcing the first line of defense.

Cells had to cope with viruses since the early days in the primordial pond. No wonder innate immune responses are so astonishingly multi-faceted, consisting of a wide array of cells, signaling chains and effector molecules solely dedicated to the elimination of infectious intruders. Viruses are the most abundant biological entities on earth, but most accidental contacts are not even noticed by us. Only those viruses which had evolved tailor-made counterstrategies can break through and establish infection for long enough to be multiplied and transmitted further. The innate immune system may be old, but as long as there are viruses (and tumors), it will never come out of fashion.

Complement and its receptors: New insights into human disease

Regulation of type I interferon responses

Control of human viral infections by natural killer cells

Induction and function of type I and III interferon in response to viral infection

An interferon paradox

Immune sensing of DNA

Dendritic cells in a mature age

Interferon-stimulated genes and their antiviral effector functions

Viral tricks to grid-lock the type I interferon system

Double-stranded RNA is produced by positive-strand RNA viruses and DNA viruses, but not in detectable amounts by negative-strand RNA viruses

Antiviral mechanisms of human defensins